Synonym
BIIB014; BIIB-014; BIIB 014; CEB-4520; CEB 4520; CEB4520; V-2006; V2006; V 2006; VER-11135; VER-A00-11; VER-A00049; VER-ADO-49; Vipadenant
IUPAC/Chemical Name
3-(4-amino-3-methylbenzyl)-7-(furan-2-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine
InChi Key
HQSBCDPYXDGTCL-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H15N7O/c1-9-7-10(4-5-11(9)17)8-23-15-14(21-22-23)13(19-16(18)20-15)12-3-2-6-24-12/h2-7H,8,17H2,1H3,(H2,18,19,20)
SMILES Code
NC1=NC(C2=CC=CO2)=C(N=NN3CC4=CC=C(N)C(C)=C4)C3=N1
Appearance
White to off-white solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Vipadenant (BIIB-014; CEB-4520) is an adenosine receptor antagonist, with Kis of 1.3 nM and 68 nM for A2A and A1, respectively.
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
37.0 |
115.14 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
321.34
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
TBD
1: Xu C, Jiang Y, Huang J, Huang J, Pu K. Second Near-Infrared Light-Activatable Polymeric Nanoantagonist for Photothermal Immunometabolic Cancer Therapy. Adv Mater. 2021 Sep;33(36):e2101410. doi: 10.1002/adma.202101410. Epub 2021 Jul 23. PMID: 34296785.
2: Lai TH, Schröder S, Toussaint M, Dukić-Stefanović S, Kranz M, Ludwig FA, Fischer S, Steinbach J, Deuther-Conrad W, Brust P, Moldovan RP. Development of 18F-Labeled Radiotracers for PET Imaging of the Adenosine A2A Receptor: Synthesis, Radiolabeling and Preliminary Biological Evaluation. Int J Mol Sci. 2021 Feb 25;22(5):2285. doi: 10.3390/ijms22052285. PMID: 33669003; PMCID: PMC7956753.
3: Shin SH, Park MH, Byeon JJ, Lee BI, Park Y, Kim N, Choi J, Shin YG. Analysis of Vipadenant and Its In Vitro and In Vivo Metabolites via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry. Pharmaceutics. 2018 Dec 3;10(4):260. doi: 10.3390/pharmaceutics10040260. PMID: 30513962; PMCID: PMC6321172.
4: Pinna A. Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs. 2014 May;28(5):455-74. doi: 10.1007/s40263-014-0161-7. PMID: 24687255.
5: Jones N, Bleickardt C, Mullins D, Parker E, Hodgson R. A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats. Brain Res Bull. 2013 Sep;98:163-9. doi: 10.1016/j.brainresbull.2013.07.001. Epub 2013 Jul 6. PMID: 23838432.
6: Brooks DJ, Papapetropoulos S, Vandenhende F, Tomic D, He P, Coppell A, O'Neill G. An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers. Clin Neuropharmacol. 2010 Mar-Apr;33(2):55-60. doi: 10.1097/WNF.0b013e3181d137d2. PMID: 20375654.
